minoxidil/finasteride (CG2001) / Beijing Dayspring Pharmaceutical - LARVOL DELTA

Advances in Medicalized Hair Loss Solutions: A Review of Current Clinical Practices and Regenerative Medicine-Based Protocols with Focus on Off-Label Injectable Treatments. (PubMed, J Clin Med) - "By stimulating hair follicle reactivation, these treatments aim to promote sustained and natural hair growth, providing individuals with more effective and durable solutions. The enhanced safety profiles of these injectable therapies, compared to conventional systemic pharmacological treatments (minoxidil, finasteride), offer a substantial improvement in patient care, addressing a widespread clinical need."

Journal • Review • Alopecia • CNS Disorders • Immunology

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=110 | Completed | Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies. (PubMed, Front Pharmacol) - "In this narrative review, we integrate evidence from large genetic studies, targeted pharmacogenetic cohorts, transcriptomic and pathway analyses, and preclinical models to delineate how genetic architecture informs disease mechanisms and modulates the effects of established therapies such as topical and oral minoxidil, finasteride, dutasteride, and prostaglandin-directed approaches. We also discuss emerging targets, including IGF1R, WNT10A, PPARGC1A, and prolactin receptor signalling, and examine how RNA based androgen receptor silencing and stem-cell-derived regenerative strategies exploit these pathways. Together, these data support a shift from empirical prescribing towards genetically informed, mechanism anchored treatment algorithms for male pattern hair loss, in which pharmacogenetic markers, polygenic scores, and multi omic readouts are progressively incorporated into therapeutic decision making and the design of future clinical trials."

Journal • Review • Alopecia • Immunology • AR • PPARGC1A

Androgenetic alopecia: an international expert view on the aetiopathogenesis, quality of life and current and emerging therapeutic approaches. (PubMed, Eur J Dermatol) - "Recent research evidenced that targeting the hair follicle and the surrounding tissue, rather than solely relying on solutions offered by minoxidil, finasteride, or other products, provides a safe and highly beneficial improvement of AGA. These innovations offer compelling early intervention strategies, potentially delaying reliance on lifelong pharmaceutical regimens and optimizing the overall patient journey and quality of life. In addition to current treatment options of AGA, novel topical non-pharmacological therapeutic options are available, helping to safely and efficiently treat this multifactorial hair condition."

HEOR • Journal • Review • Alopecia • Immunology

Topical Cetirizine in Androgenetic Alopecia: A Preliminary Study. (PubMed, Skin Appendage Disord) - "Exclusion criteria included recent use of minoxidil, finasteride, or other antiandrogenic therapies. Despite limitations, this report provides additional real-world data supporting cetirizine as a potential therapy in AGA. Larger randomized controlled studies with longer follow-up are needed to establish efficacy, durability, and mechanism of action."

Journal • Alopecia • Immunology

Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study. (PubMed, J Dermatolog Treat) - "Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males with androgenetic alopecia (AGA). Steady state was achieved for both drugs after 7 days. The favorable safety profile and reduced systemic finasteride exposure position CG2001 as a promising alternative, supporting further clinical development in a phase IIa trial, and provide a pharmacokinetic foundation for subsequent efficacy trials in patients with AGA."

Clinical • Journal • P1 data • PK/PD data • Addiction (Opioid and Alcohol) • Alopecia • Immunology

O04 Pharmacological efficacy of low-dose oral minoxidil-finasteride combination for hair growth and stability in male androgenetic alopecia: a 12-month retrospective service evaluation. (PubMed, Br J Dermatol) - "Nonetheless, modest κ-values reinforce the necessity for objective imaging protocols or artificial intelligence-driven methods in future research. Prospective, controlled trials incorporating explicit safety monitoring and patient-reported outcomes are warranted to optimize dosing and validate long-term tolerability."

Journal • Retrospective data • Alopecia • Immunology

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: EMS | Trial completion date: Sep 2025 ➔ Sep 2027 | Trial primary completion date: Apr 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Updates in Treatment for Androgenetic Alopecia. (PubMed, Ann Dermatol) - "Topical minoxidil and oral finasteride are the most widely used treatments for AGA, addressing follicular miniaturization...Finasteride and dutasteride, both 5-α-reductase inhibitors that reduce DHT levels in hair follicles, are key androgen-targeting treatments, with newer formulations like topical and injectable options emerging alongside traditional oral forms...This review explores current and emerging treatments for AGA, addressing both androgen-targeted and non-androgen-targeted approaches with an emphasis on their mechanisms, efficacy, and safety. It ultimately aims to provide a comprehensive update on the latest advancements in AGA management."

Journal • Review • Alopecia • CNS Disorders • Immunology

Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Med (Lausanne)) - "However, larger, standardized trials are needed to confirm long-term outcomes and optimize treatment protocols. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251054497, identifier CRD420251054497."

Journal • Retrospective data • Review • Alopecia • Immunology

Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry (PubMed, Se Pu) - "Anti-alopecia cosmetics are often found to contain illegal additions of prohibited drugs such as minoxidil， finasteride and other substances...An ultra-high performance liquid chromatography-multiple reaction monitoring-information dependent acquisition-enhanced production scanning （UHPLC-MRM-IDA-EPI） method was developed to determine 13 JAK inhibitors in anti-alopecia cosmetics， including baricitinib， tofacitinib， ritlecitinib， peficitinib， abrocitinib， upadacitinib， ivarmacitinib， fedratinib， filgotinib， ruxolitinib， momelotinib， pacritinib and bozitinib...Recoveries of the 13 JAK inhibitors ranged from 94.7% to 102.2% for the water-soluble matrix and from 92.4% to 99.2% for the cream matrix， with relative standard deviations （RSDs） ≤8.8%. This method is characterized by high efficiency， rapidity， accuracy， sensitivity and simplicity， making it a powerful tool for rapid risk screening and simultaneous quantitative analysis of JAK inhibitors in anti-alopecia cosmetics."

Journal • Alopecia • Immunology

Trichology in the Age of Misinformation: Bridging the Gap Between Evidence-Based Dermatology and Social Media Narratives (EADV 2025) - "Despite the availability of evidence-based treatments such as Minoxidil, Finasteride, Dutasteride, and Platelet-Rich Plasma (PRP), patients are frequently exposed to misinformation that promotes unverified, often ineffective remedies. Misinformation in trichology poses a growing challenge to evidence-based dermatology. However, it also offers an opportunity for dermatologists to reclaim the narrative through responsible use of social media and enhanced patient communication. By actively addressing myths, setting realistic expectations, and simplifying scientific information for digital platforms, dermatologists can build credibility, improve adherence, and protect patients from the pitfalls of pseudoscience."

Alopecia • Dermatology

Comparative Analysis of Platelet-Rich Plasma (PRP), Exosomes, and Minoxidil Therapy for Androgenic Alopecia (EADV 2025) - "Current treatments include minoxidil, finasteride, platelet-rich plasma (PRP), and novel regenerative approaches like exosome therapy. The results of this comparison highlight the strong promise of exosome therapy as a groundbreaking treatment for androgenic alopecia.. With its ability to induce rapid and robust follicular regeneration evidenced by near- complete vellus hair reduction, full anagen induction, and complete telogen suppression, exosome therapy demonstrates clear advantages over conventional treatments like PRP and minoxidil."

Alopecia • Immunology

Assessing safety and efficacy of a mixture of oral finasteride 1 mg, minoxidil 1 mg, and biotin 5 mg in treatment of androgenetic alopecia in males: a single-arm, before-after clinical trial (EADV 2025) - "Current treatments for AGA include minoxidil, finasteride, dutasteride, injections, microneedling, low-level laser therapy, and hair transplant. The oral combination of finasteride 1 mg, minoxidil 1 mg, and biotin 5 mg seems to be a safe and effective combination for treatment of AGA males with Norwood scale II-IV. The effectiveness seems to be mostly driven by objective increased duration of anagen phase. Larger controlled and randomized clinical trials in different settings and on different age and sex groups are needed to confirm results of this clinical trial."

Clinical • Aesthetic Medicine • Alopecia • Fatigue • Immunology • AR

Analysis of Hair Loss Severity and Treatment Approaches in 100 Male Patients with Androgenetic Alopecia (EADV 2025) - "Patients were categorized into the following groups: Stages 1–3: 51 patients, Stages 4–5: 31 patients, Stages 6–7: 18 patients Detailed medical history and prior treatments were recorded, including the use of finasteride, minoxidil, and local therapies (e.g., mesotherapy, platelet-rich plasma). Effective treatment for androgenetic alopecia is often initiated too late, which limits the success of hair transplantation. Early pharmacological intervention with finasteride and minoxidil can improve the overall condition of the scalp and increase the success rate of FUE procedures. Hair loss exceeding stage 6 on the Hamilton-Norwood scale presents challenges for successful transplantation due to limited donor site availability."

Clinical • Aesthetic Medicine • Alopecia • Immunology

Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia. (PubMed, Pharmaceutics) - "Traditional treatment options, including minoxidil, finasteride, and hair transplantation, have their limitations, such as skin irritation, systemic side effects, invasiveness, and high costs. It analyzes the underlying mechanisms that enhance drug penetration through hair follicles. Finally, this review presents a forward-looking perspective on the future use of TDDS in the management of AGA, aiming to provide insights and references for designing effective transdermal drug delivery systems for this condition."

Journal • Review • Aesthetic Medicine • Alopecia • Immunology • Transplantation

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. (PubMed, Aesthetic Plast Surg) - "Subsequently, a comprehensive analysis of the predominant product categories and ingredients currently available on the market was conducted, encompassing minoxidil, finasteride, plant extracts, growth factors, and peptides. By synthesizing extant research and delineating prospective research directions, this paper establishes an indispensable reference point for the research and development of cosmetics designed to promote hair growth and prevent hair loss.Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 ."

Journal • Review • Alopecia • Gene Therapies • Immunology

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd

New P2 trial • Alopecia • Dermatology • Immunology

Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd

New P1 trial • Alopecia • Dermatology • Immunology